Mg. Dunckley et al., MODIFICATION OF SPLICING IN THE DYSTROPHIN GENE IN CULTURED MDX MUSCLE-CELLS BY ANTISENSE OLIGORIBONUCLEOTIDES, Human molecular genetics (Print), 7(7), 1998, pp. 1083-1090
Deletions and point mutations in the gene encoding the cytoskeletal pr
otein dystrophin and its isoforms cause either the severe progressive
myopathy Duchenne muscular dystrophy (DMD) or the milder Decker muscul
ar dystrophy (BMD), largely depending on whether the reading frame is
lost or maintained respectively, Frameshift mutations tend to result i
n a lack of dystrophin at the sarcolemma, destabilization of the membr
ane and degeneration of skeletal muscle, The mdx mouse is a valuable a
nimal model of DMD as it bears a nonsense point mutation in exon 23 of
the murine DMD gene leading to an absence of dystrophin expression in
the muscle sarcolemma and muscular dystrophy, This report represents
a novel approach to correct dystrophin deficiency at the post-transcri
ptional level by transfection of muscle cells with antisense RNA. Esse
ntially, 2'-O-methyl oligoribonucleotides (2'OMeRNA) were delivered to
the nuclei of primary mdx myoblasts in culture. Dystrophin expression
was observed in the sarcolemma of transfected mdx myotubes after tran
sfection by an oligonucleotide complementary to the 3' splice site of
murine dystrophin intron 22, Direct sequencing of RT-PCR products from
these cells revealed precise splicing of exon 22 to exon 30, skipping
the mutant exon and creating a novel in-frame dystrophin transcript.
As patients with comparable in-frame internal deletions show relativel
y mild myopathic symptoms, this may in the future offer a therapeutic
approach for DMD, as well as for other inherited disorders.